Generic competition to GlaxoSmithKline ($GSK) respiratory behemoth Advair could finally be on the horizon, and Mylan ($MYL) wants to make sure it gets a piece of the med's blockbuster revenues. On Friday, the company announced that the FDA had accepted its application for a copy of the blockbuster, with a decision date set for March 28, 2017. Mylan joins Hikma and Novartis' ($NVS) Sandoz, which have already made FDA submissions. Release